- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00938327
Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Indian Infants
Post Marketing Surveillance to Monitor the Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus Vaccine, Rotarix™ When Administered According to the Prescribing Information to Indian Infants
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
-
Bangalore, Indien, 560 011
- GSK Investigational Site
-
Bangalore, Indien, 560 095
- GSK Investigational Site
-
Chennai, Indien, 600 033
- GSK Investigational Site
-
Delhi, Indien, 110085
- GSK Investigational Site
-
Delhi, Indien, 110088
- GSK Investigational Site
-
Kolkata, Indien, 700064
- GSK Investigational Site
-
Kolkata, Indien
- GSK Investigational Site
-
Mumbai, Indien, 400 053
- GSK Investigational Site
-
Mumbai, Indien, 400081
- GSK Investigational Site
-
Mumbai, Indien
- GSK Investigational Site
-
New Delhi, Indien, 110087
- GSK Investigational Site
-
Pune, Indien, 411044
- GSK Investigational Site
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in this PMS.
- A male or female infant, from the age of 6 weeks at the time of the first vaccination and less than 24 weeks of age at the time of second vaccination.
- Written informed consent obtained from the parent or guardian of the subject.
Exclusion Criteria:
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- Concurrently participating in another clinical study, at any time during the surveillance period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).
- Acute disease at the time of enrolment.
- Any history of uncorrected congenital malformation of the gastrointestinal tract that would predispose the subject for intussusception.
- Known hypersensitivity after previous administration of rotavirus vaccine or to any component of the vaccine.
- Gastroenteritis within 7 days preceding vaccination.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: Kohorte
- Zeitperspektiven: Interessent
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
---|---|
Rotarix Group
Subjects who have received 2 oral doses (or a second dose for subjects who had already received the first dose prior to joining the study) of Rotarix™ at an interval of not less than 4 weeks between the doses.
|
Two doses of oral vaccine.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Number of Subjects Reporting Grade 2 or 3 Symptoms (Fever, Vomiting or Diarrhoea)
Zeitfenster: During the 8-day (Day 0 - Day 7) follow-up period after each vaccination.
|
Grade 2 fever was defined as axillary temperature above 38.0 degrees Celsius (°C) and below or equal to 39.0°C. Grade 3 fever was defined as axillary temperature above 39.0°C. Grade 2 vomiting was defined as 2 episodes of vomiting per day. Grade 3 vomiting was defined as at least 3 episodes of vomiting per day. Grade 2 diarrhoea was defined as 4-5 looser than normal stools per day. Grade 3 diarrhoea was defined as at least 6 looser than normal stools per day. |
During the 8-day (Day 0 - Day 7) follow-up period after each vaccination.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Number of Subjects Reporting Solicited General Symptoms
Zeitfenster: During the 8-day (Day 0 - Day 7) follow-up period after each vaccination
|
Cough: Cough/runny nose of any intensity Diarrhoea: Passage of three or more looser than normal stools within a day Irritability: Cried more than usual Loss of appetite: Ate less than usual Temperature: Axillary temperature greater than or equal to 37.5°C Vomiting: One or more episodes of forceful emptying of partially digested stomach contents ≥ 1 hour after feeding within a day
|
During the 8-day (Day 0 - Day 7) follow-up period after each vaccination
|
Number of Subjects Reporting Unsolicited Adverse Events (AEs)
Zeitfenster: During the 31-day (Day 0 - Day 30) follow-up period after each vaccination
|
Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
|
During the 31-day (Day 0 - Day 30) follow-up period after each vaccination
|
Number of Subjects Reporting Serious Adverse Events (SAEs)
Zeitfenster: Throughout the study period (from Day 0 up to Day 30)
|
SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.
|
Throughout the study period (from Day 0 up to Day 30)
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Ruberu D et al. Post-marketing surveillance of a live-attenuated human rotavirus vaccine (Rotarix™) in India and Sri Lanka. Abstract presented at the 9th International Congress of Tropical Pediatrics (ICTP). Bangkok, Thailand, 18-20 October 2011.
- Bravo L, Chitraka A, Liu A, Choudhury J, Kumar K, Berezo L, Cimafranca L, Chatterjee P, Garg P, Siriwardene P, Bernardo R, Mehta S, Balasubramanian S, Karkada N, Htay Han H. Reactogenicity and safety of the human rotavirus vaccine, Rotarix in The Philippines, Sri Lanka, and India: a post-marketing surveillance study. Hum Vaccin Immunother. 2014;10(8):2276-83. doi: 10.4161/hv.29280.
- Kumar k et al. Safety and reactogenicity of RIX4414 live attenuated human rotavirus vaccine: An Indian post-marketing surveillance study. Abstract presented at the 48th National Conference of Indian Academy of Pediatrics (Pedicon). Jaipur, India, 19-23 January 2011.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 112896
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Infektionen, Rotaviren
-
GlaxoSmithKlineAbgeschlossenRotavirus-Infektion | Rotavirus-ImpfstoffeVereinigte Staaten
-
PATHBill and Melinda Gates Foundation; Children's Hospital Medical Center, Cincinnati und andere MitarbeiterAbgeschlossen
-
Taipei Medical University Shuang Ho HospitalUnbekannt
-
National Institute of Pediatrics, MexicoMerck Sharp & Dohme LLC; Centro Nacional para la Salud de la Infancia y la AdolescenciaAbgeschlossen
-
GlaxoSmithKlineAbgeschlossenRotavirus-Gastroenteritis | Nosokomiale Rotavirus-Gastroenteritis
-
Seattle Children's HospitalNational Center for Research Resources (NCRR); Thrasher Research FundAbgeschlossenDarmversagen | Rotavirus-ImpfstoffeVereinigte Staaten
-
Romark Laboratories L.C.AbgeschlossenRotavirus-Infektion | Virale Gastroenteritis durch RotavirusÄgypten
-
PATHAbgeschlossenRotavirus-InfektionVereinigte Staaten
-
Merck Sharp & Dohme LLCAbgeschlossen
-
PATHAbgeschlossenBewertung eines Rotavirus-ImpfstoffsSüdafrika
Klinische Studien zur Rotarix™
-
Telethon Kids InstituteMenzies School of Health ResearchAktiv, nicht rekrutierendVirale Gastroenteritis durch RotavirusAustralien
-
GlaxoSmithKlineAbgeschlossenInfektionen, RotavirenSri Lanka
-
GlaxoSmithKlineAbgeschlossenInfektionen, Rotaviren | Rotavirus-ImpfstoffeKorea, Republik von
-
GlaxoSmithKlineAbgeschlossenInfektionen, RotavirenSpanien, Polen, Frankreich, Portugal
-
GlaxoSmithKlineAbgeschlossenInfektionen, RotavirenChina
-
GlaxoSmithKlineAbgeschlossenInfektionen, RotavirenChina
-
GlaxoSmithKlineZurückgezogenInfektionen, Rotaviren
-
GlaxoSmithKlineAbgeschlossenInfektionen, Rotaviren | Rotavirus-ImpfstoffePhilippinen
-
GlaxoSmithKlineAbgeschlossen
-
GlaxoSmithKlineAbgeschlossenTetanus | Diphtherie | Azelluläre Keuchhusten | Poliomyelitis | Haemophilus influenzae Typ bKorea, Republik von